Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability
US8541369B2 · kind B2 · utility
40Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2012 |
| Grant date | Sep 24, 2013 |
| Priority date | — |
| Expiry date | Sep 25, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.